PCID2

Across TCGA pan-cancer cohorts, PCID2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PCID2 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PCID2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PCID2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, LSCC, and UCEC are the cancer types where PCID2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.996	0.793	.001	35	view →
LSCC	OS	Tertile	III,IV	0.746	1.000	.038	5	view →
UCEC	DFS	Tertile	All	0.779	0.949	.030	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PCID2–LUAD (DFS)

Open the LUAD breakdown →